Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 6/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.39 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251226 | 1.00 | GPR119 (0.44) | GPR119NR1H2NR1H3CXCR3SMO | |
| SCHEMBL4251039 | 0.91 | CXCR3 (0.40) | GPR119NR1H2NR1H3CXCR3SMO | |
| SCHEMBL4244159 | 0.91 | CXCR3 (0.40) | GPR119NR1H2NR1H3CXCR3SMO | |
| SCHEMBL4249184 | 0.89 | CXCR3 (0.40) | NR1H2NR1H3CXCR3SMOSGPL1 | |
| SCHEMBL4249188 | 0.89 | CXCR3 (0.40) | NR1H2NR1H3CXCR3SMOSGPL1 | |
| SCHEMBL4398201 | 0.89 | PTGDR2 (0.42) | NR1H2NR1H3CXCR3SMOSGPL1 | |
| SCHEMBL4244454 | 0.88 | SGPL1 (0.41) | CXCR3SMOSGPL1 | |
| SCHEMBL13592416 | 0.88 | SGPL1 (0.41) | CXCR3SMOSGPL1 | |
| SCHEMBL14311334 | 0.88 | SGPL1 (0.41) | CXCR3SMOSGPL1 | |
| SCHEMBL13590836 | 0.88 | SGPL1 (0.41) | CXCR3SMOSGPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | claimed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | claimed |
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | GPR119 970/4885NR1H2 2242/4885NR1H3 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.